Pregnenolone is a precursor steroid hormone synthesized from cholesterol in the mitochondria of adrenal glands, gonads, and brain tissue. Often called the "mother hormone," it serves as the foundational building block for all other steroid hormones — including testosterone, DHEA, cortisol, progesterone, and estrogen.
Available over the counter as a dietary supplement, pregnenolone lacks FDA approval for testosterone replacement therapy or hypogonadism treatment. It's sometimes added to TRT protocols as an adjunctive therapy — notably in Maximus's King Protocol alongside enclomiphene — with the hypothesis that exogenous testosterone may suppress upstream steroidogenesis, limiting production of pregnenolone and its downstream neurosteroid metabolites.
This is not a testosterone replacement. Pregnenolone does not directly raise testosterone levels in any clinically proven way.
The rationale for adding pregnenolone to TRT focuses on neurosteroid support rather than testosterone production. When you inject or apply testosterone exogenously, your hypothalamic-pituitary-adrenal axis downregulates natural steroid synthesis. Some clinicians theorize this suppression extends to pregnenolone-derived neurosteroids like allopregnanolone, which modulate GABA receptors and influence mood, cognition, and stress response.1
Current positioning in the TRT landscape: pregnenolone occupies a niche as an experimental adjunct rather than a core treatment. Most TRT protocols — including standard testosterone cypionate, gels, and pellets — do not include pregnenolone supplementation. Its use remains largely anecdotal, driven by integrative medicine practitioners and telehealth providers experimenting with hormone optimization beyond testosterone alone.
Pregnenolone sits in the broader category of hormone precursors and TRT adjuncts — supplements added to testosterone therapy with the goal of optimizing downstream effects or mitigating side effects.
DHEA is the closest comparator. Like pregnenolone, DHEA is a steroid hormone precursor available over the counter. DHEA converts directly to androgens and estrogens, while pregnenolone sits one step earlier in the pathway. Some men use both, hypothesizing they support different branches of steroidogenesis. Evidence is equally thin for both.
Human chorionic gonadotropin (hCG) represents a fertility-preserving TRT adjunct with far stronger evidence. Unlike pregnenolone, hCG maintains testicular function by mimicking LH, supporting endogenous testosterone and sperm production. Men concerned about fertility should prioritize hCG over experimental neurosteroid support.
Enclomiphene — a selective estrogen receptor modulator that preserves fertility while raising testosterone — pairs with pregnenolone in some protocols like Maximus's King Protocol. The theory: enclomiphene maintains upstream signaling (LH/FSH), while pregnenolone supplements neurosteroid pathways potentially suppressed during treatment. No trials validate this combination.
For cognitive support during TRT, lifestyle interventions carry more evidence than pregnenolone. Sleep optimization, resistance training, stress management, and addressing comorbidities like sleep apnea or depression have documented benefits. Pregnenolone is a speculative add-on at best.
If you're exploring alternative delivery methods for core TRT, focus on testosterone gels, pellets, or newer oral formulations like testosterone undecanoate rather than investing effort in unproven adjuncts. Get the foundation right before experimenting with peripherals.
Pregnenolone's mechanism centers on its role as the first steroid hormone synthesized from cholesterol. The enzyme cytochrome P450 side-chain cleavage enzyme (P450scc) converts cholesterol to pregnenolone inside mitochondria. From there, pregnenolone branches into two major pathways: one leading to progesterone and cortisol, the other to DHEA and ultimately testosterone and estrogen.1
At the cellular level, pregnenolone and its metabolites modulate neurotransmitter receptors. It acts as a positive allosteric modulator of GABA_A receptors, enhancing inhibitory neurotransmission that dampens anxiety and promotes calm. It also influences NMDA receptors, supporting neuroprotection and potentially improving memory consolidation.1
The neurosteroid allopregnanolone — a downstream metabolite of pregnenolone — delivers much of the anxiolytic and mood-stabilizing effects attributed to the parent compound. This is why some clinicians prescribe pregnenolone for cognitive function and mood during TRT, hypothesizing that exogenous testosterone suppresses endogenous pregnenolone synthesis.
But here's the problem: no clinical trials demonstrate that TRT actually suppresses pregnenolone levels, or that supplementing pregnenolone restores any measurable benefit in hypogonadal men. The theory is plausible. The evidence is absent.
Pharmacokinetically, oral pregnenolone absorbs rapidly, reaching peak plasma concentrations within 1-2 hours. Bioavailability is low — estimated at 5-10% — due to extensive first-pass metabolism in the liver, where it undergoes sulfation and rapid conversion to downstream steroids like progesterone and DHEA.1 The half-life of unmetabolized pregnenolone is approximately 1-2 hours, but metabolites persist longer, extending its biological effects.
Most clinical data comes from psychiatric research, not TRT. A proof-of-concept randomized controlled trial in 21 patients with schizophrenia tested adjunctive pregnenolone at escalating doses up to 500 mg daily over eight weeks. The trial showed significant reductions in negative symptoms (apathy, social withdrawal) measured by SANS scores compared to placebo, with a mean change of -10.38 versus -2.33 (p=0.048).1 Global clinical improvement also favored pregnenolone (CGI-I scores 2.11 vs 2.89, p=0.015).
Cognitive outcomes were less impressive. The same trial found no significant improvements on BACS or MCCB composite scores, despite hypotheses that pregnenolone would enhance memory and executive function through neurosteroid pathways.1
A separate RCT in 94 veterans with chronic low back pain tested pregnenolone at doses escalating from 100 mg to 500 mg daily over four weeks. Pain reduction was modest — approximately 20% versus 6% in placebo — but the trial found no benefits for sleep, mood, memory, or functional capacity. Importantly, no testosterone or hormonal endpoints were measured.2
Time to therapeutic effect varies by indication. In the schizophrenia trial, symptom changes emerged by week 4-8, with the final four weeks at full dose (500 mg daily) driving primary outcomes.1 No TRT-specific data exists on when patients might notice cognitive or mood improvements when adding pregnenolone to testosterone therapy.
Response rates remain uncharacterized in the TRT population. The schizophrenia trial achieved 86% completion rate (18 of 21 patients completing at least four weeks), suggesting tolerability in that cohort. Whether hypogonadal men on TRT respond similarly — or at all — is unknown.
No clinical practice guidelines from major endocrine societies recommend pregnenolone for testosterone replacement therapy or hypogonadism. The Endocrine Society's TRT guidelines do not mention pregnenolone. You're operating in uncharted territory if you add this to your protocol.
Standard dosing in available trials ranges from 30 mg to 500 mg daily, taken orally. The schizophrenia trial used an escalation protocol: 100 mg daily at week 2, increasing to 200 mg twice daily by week 4, and reaching 500 mg daily (split into two doses) by weeks 5-6.1 The back pain trial similarly escalated from 100 mg to 500 mg over four weeks.2
Over-the-counter pregnenolone supplements typically come in 10-50 mg capsules. Some integrative clinics prescribe compounded pregnenolone at higher doses (100-200 mg daily) when adding it to TRT protocols, usually as a single morning dose or split into twice-daily administration to match its short half-life.
| Parameter | Standard Approach | Notes |
|---|---|---|
| Starting Dose | 50-100 mg daily | OTC formulations typically 50 mg capsules taken once daily with food |
| Administration Frequency | Once daily (morning) or split BID | Short half-life (1-2 hours) may favor divided dosing |
| Dose Escalation | Increase by 50 mg every 2-4 weeks if needed | Trial data supports doses up to 500 mg daily, but no TRT-specific guidance |
| Lab Monitoring (Baseline) | Serum pregnenolone, testosterone, DHEA-S, cortisol | Establish baseline steroid profile before supplementation |
| Lab Monitoring (Follow-up) | Repeat at 6-8 weeks, then every 6 months | Track pregnenolone levels and downstream hormone changes |
| Symptom Tracking | Cognitive function, mood, energy, sleep quality | No validated instruments exist for TRT + pregnenolone outcomes |
Lab monitoring lacks standardization. Unlike testosterone therapy's established protocols for hematocrit, PSA, and lipid panels, pregnenolone supplementation has no consensus monitoring framework. Some practitioners measure serum pregnenolone levels to confirm absorption and dose response, correlating levels with symptom changes as done in psychiatric trials.1
Downstream hormone effects warrant attention. Because pregnenolone converts to progesterone, DHEA, and cortisol, high-dose supplementation could theoretically alter these pathways. Checking DHEA-S and cortisol levels at baseline and follow-up helps identify unexpected shifts, though clinical significance remains unclear.
No protocol variations exist for TRT-specific populations. Observational data suggests shift workers and men with circadian disruption show altered pregnenolone and testosterone patterns,3 raising questions about whether dosing should adjust for sleep schedules or stress levels. No trials address this.
When combined with fertility-preserving TRT like enclomiphene (as in the Maximus King Protocol), the rationale is supporting neurosteroid production without further suppressing the HPT axis. Enclomiphene maintains LH and FSH signaling, theoretically preserving some endogenous pregnenolone synthesis. Adding exogenous pregnenolone aims to fill any remaining gap. Evidence for this combination? Zero published studies.
Pregnenolone was well-tolerated in psychiatric and pain trials, with no significant adverse events reported versus placebo.1 The schizophrenia RCT tracked safety through biweekly visits and phone checks using standardized adverse event forms. Back pain trials similarly found no serious events during dose escalation up to 500 mg daily.2
Common side effects at typical OTC doses (50-100 mg daily) include headache and mood swings. These occur more frequently during the first 2-4 weeks as the body adjusts to altered neurosteroid tone. Most resolve without intervention.
Higher doses above 200 mg daily carry increased risk of hormone-related effects. Because pregnenolone converts to progesterone and DHEA, some users report acne, oily skin, irritability, or fluid retention — symptoms similar to those seen with DHEA supplementation. No systematic documentation of incidence rates exists for these effects in the TRT population.
| Frequency | Mild | Moderate | Severe |
|---|---|---|---|
| Common (>10%) | Headache (early weeks), mild fatigue | Mood swings, irritability | — |
| Occasional (1-10%) | Acne, oily skin (high doses) | Insomnia, vivid dreams | — |
| Rare (<1%) | — | Fluid retention | Seizure threshold reduction (theoretical at very high doses) |
Contraindications include hormone-sensitive cancers. Because pregnenolone feeds into pathways producing estrogen, progesterone, and testosterone, men with prostate cancer or other hormone-dependent malignancies should avoid supplementation. No trials have tested pregnenolone in cancer populations, making risk assessment speculative but biologically plausible.
Seizure disorders represent another contraindication. High doses of pregnenolone may reduce seizure threshold through neurosteroid modulation of GABA receptors, though documented cases are absent. Men with epilepsy or history of seizures should not use pregnenolone without neurologist consultation.
Drug interactions remain poorly characterized. Pregnenolone's extensive hepatic metabolism via CYP enzymes creates theoretical interaction potential with other medications metabolized through the same pathways — including some statins, anticoagulants, and psychiatric drugs. No formal interaction studies exist.
Warning signs requiring immediate medical attention include sudden mood changes (severe depression or anxiety), rapid heart rate, chest pain, or signs of allergic reaction. While none of these occurred in trials, the unregulated nature of OTC pregnenolone supplements raises quality and purity concerns that could trigger unexpected reactions.
Long-term safety data is absent. The longest trial duration was 12 weeks. Whether years of pregnenolone supplementation affects cancer risk, cardiovascular health, or hormone-dependent tissues remains unknown. You're essentially conducting an uncontrolled experiment on yourself.
Pregnenolone is available over the counter without prescription. You can purchase it at supplement retailers, health food stores, online marketplaces, and through compounding pharmacies that formulate custom doses.
OTC pregnenolone supplements fall under the Dietary Supplement Health and Education Act (DSHEA) of 1994, meaning the FDA does not evaluate these products for safety or efficacy before they reach consumers. Quality varies wildly between brands. Third-party testing by organizations like USP or NSF provides some assurance of label accuracy, but most pregnenolone products lack such certification.
Typical pricing ranges from $15-50 per month depending on dose and brand. A 60-count bottle of 50 mg capsules costs approximately $15-25 at major supplement retailers. Higher-dose formulations (100 mg or custom compounded doses) run $30-50 monthly. This makes pregnenolone one of the most affordable hormone-related supplements.
Insurance does not cover over-the-counter pregnenolone. Prescription compounded pregnenolone — sometimes written by integrative or functional medicine providers — also typically falls outside insurance coverage. However, pregnenolone qualifies for FSA and HSA reimbursement when purchased with a letter of medical necessity from your provider.
To access pregnenolone as part of a TRT protocol, discuss it with your prescribing physician. Most mainstream endocrinologists and urologists will not recommend it due to lack of evidence. Integrative medicine doctors, naturopathic physicians, and some telehealth TRT providers are more likely to incorporate pregnenolone into optimization protocols.
Telehealth platforms like Maximus include pregnenolone in specialty protocols (such as the King Protocol combining enclomiphene and pregnenolone). These services handle prescribing, compounding, and delivery — typically at higher cost than OTC supplements but with medical oversight and standardized dosing.
Compounding pharmacies can formulate custom pregnenolone doses (100-200 mg capsules) when prescribed by a licensed provider. This approach ensures pharmaceutical-grade quality and precise dosing but adds cost compared to OTC options. Expect to pay $40-80 monthly for compounded pregnenolone, plus consultation fees.
Who should consider pregnenolone as a TRT adjunct? The ideal candidate is theoretical: a man on testosterone therapy experiencing persistent brain fog, mood symptoms, or cognitive dulling despite optimized testosterone levels, who hypothesizes that suppressed neurosteroid production contributes to symptoms. This patient accepts the lack of evidence and wants to experiment under medical supervision.
Most men on standard TRT will see no benefit from adding pregnenolone. If your testosterone levels are dialed in, symptoms are controlled, and you're not experiencing cognitive or mood issues, there's no evidence-based reason to add pregnenolone. Save your money.